These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28529511)

  • 21. HLAII peptide presentation of infliximab increases when complexed with TNF.
    Casasola-LaMacchia A; Seward RJ; Tourdot S; Willetts M; Kruppa G; Agostino MJ; Bergeron G; Ahyi-Amendah N; Ciarla A; Lu Z; Kim HY; Hickling TP; Neubert H
    Front Immunol; 2022; 13():932252. PubMed ID: 36177046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T cell alloresponses against HLA-DQ and -DR products involve multiple epitopes on the CD4 molecule. Distinct mechanisms contribute to the inhibition of HLA class II-dependent and -independent T cell responses by antibodies to CD4.
    Merkenschlager M; Altmann DM; Ikeda H
    J Immunol; 1990 Nov; 145(10):3181-7. PubMed ID: 1699999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical Proteins.
    Andrick BJ; Schwab AI; Cauley B; O'Donnell LA; Meng WS
    PLoS One; 2015; 10(8):e0135451. PubMed ID: 26270649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
    Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
    Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively.
    Castelli FA; Houitte D; Munier G; Szely N; Lecoq A; Briand JP; Muller S; Maillere B
    Eur J Immunol; 2008 Oct; 38(10):2821-31. PubMed ID: 18828138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
    Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
    Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-helper cell-response to MHC class II-binding peptides of the renal cell carcinoma-associated antigen RAGE-1.
    Stassar MJ; Raddrizzani L; Hammer J; Zöller M
    Immunobiology; 2001 Aug; 203(5):743-55. PubMed ID: 11563674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
    Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
    Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human CD4+ T lymphocytes recognize a vascular endothelial growth factor receptor-2-derived epitope in association with HLA-DR.
    Sun Y; Song M; Jäger E; Schwer C; Stevanovic S; Flindt S; Karbach J; Nguyen XD; Schadendorf D; Cichutek K
    Clin Cancer Res; 2008 Jul; 14(13):4306-15. PubMed ID: 18594014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [T cells recognizing EBV-epitopes arose in co-culture of peripheral blood mononuclear cells from EB-infected patients and dendritic cells loaded with LMP2-mixed peptides].
    Xing YP; Cen XN; Tong CR; Gu JY; Cai P; Tao XY; Jin X; Zhu P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):392-6. PubMed ID: 18426672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of HLA-DR-restricted T-cell epitopes derived from human proteinase 3.
    Piesche M; Hildebrandt Y; Chapuy B; Wulf GG; Trümper L; Schroers R
    Vaccine; 2009 Jul; 27(34):4718-23. PubMed ID: 19446593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.
    Neumann F; Wagner C; Stevanovic S; Kubuschok B; Schormann C; Mischo A; Ertan K; Schmidt W; Pfreundschuh M
    Int J Cancer; 2004 Nov; 112(4):661-8. PubMed ID: 15382048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes.
    Vissers JL; De Vries IJ; Engelen LP; Scharenborg NM; Molkenboer J; Figdor CG; Oosterwijk E; Adema GJ
    Int J Cancer; 2002 Aug; 100(4):441-4. PubMed ID: 12115527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
    Gnjatic S; Atanackovic D; Jäger E; Matsuo M; Selvakumar A; Altorki NK; Maki RG; Dupont B; Ritter G; Chen YT; Knuth A; Old LJ
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8862-7. PubMed ID: 12853579
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+ /CD8+ T cells in humans after lipopeptide vaccination.
    Gahery H; Figueiredo S; Texier C; Pouvelle-Moratille S; Ourth L; Igea C; Surenaud M; Guillet JG; Maillere B
    AIDS Res Hum Retroviruses; 2007 Mar; 23(3):427-37. PubMed ID: 17411376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specificity of the T Cell Response to Protein Biopharmaceuticals.
    Meunier S; de Bourayne M; Hamze M; Azam A; Correia E; Menier C; Maillère B
    Front Immunol; 2020; 11():1550. PubMed ID: 32793213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of T cell epitopes by the use of rapidly generated mRNA fragments.
    Britten CM; Meyer RG; Graf C; Huber C; Wölfel T
    J Immunol Methods; 2005 Apr; 299(1-2):165-75. PubMed ID: 15914199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody.
    Xue L; Hickling T; Song R; Nowak J; Rup B
    Clin Exp Immunol; 2016 Jan; 183(1):102-13. PubMed ID: 26400440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Simple Proteomics-Based Approach to Identification of Immunodominant Antigens from a Complex Pathogen: Application to the CD4 T Cell Response against Human Herpesvirus 6B.
    Becerra-Artiles A; Dominguez-Amorocho O; Stern LJ; Calvo-Calle JM
    PLoS One; 2015; 10(11):e0142871. PubMed ID: 26599878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.